Promoter holding
64.27%
SP
Sequent Penems Private Limited - Due diligence report
A 360° intelligence report on Sequent: trust score, financial health, credit view, compliance, directors, growth and distress signals - gene…
Sequent — 360° Intelligence Report
Generated from MCA filings & public records72/100
Trust Score
Moderate
Sequent is assessed as Moderate with a Trust Score of 72/100. Sequent is an active private limited indian non-government company incorporated in 2010, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.
Report generated on 13 Jun 2026 from the latest processed filings. Sequent Penems Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
72/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
20/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
20/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 20/100 Caution Indicated
- Negative operating earnings - debt service depends on external support.
- Open charges exceed net worth - secured lenders rank ahead.
- Elevated gearing (D/E 38%).
Charges position: 1 open (10.00 cr) · 1 satisfied (90.00 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| State Bank Of Hyderabad | 1 | 48.0 cr |
| Others | 1 | 48.0 cr |
Compliance Score: 100/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- 1 active GST registration(s).
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SALIM SADIQ SHAIKH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AKASH SURESH PURANIK | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 2 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
06
Ownership & Group Intelligence
As per FY 2022 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Solara Active Pharma Sciences Limited
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 1 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Solara Active Pharma Sciences Limited | Holding Company | 74.00% |
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 60
Growth signals & trust indicators
Operating for 16+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
1 open charge(s) registered - assets are encumbered.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence80/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment40/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 10.00 cr already registered.
- Compliance record supports lending.
Investor view41/100
Limited indicators at present
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
12 Sep 2024
Charge created
Others - 10.00 cr
25 Apr 2024
Director appointed
SALIM SADIQ SHAIKH (Director)
Director appointed
AKASH SURESH PURANIK (Director)
Director ceased
VENKATRAMANI RAGHAVAN
31 Mar 2022
Share transfer (FY 2022)
13750.00000000 shares to Solara Active Pharma Sciences Limit
14 Aug 2019
Director ceased
SWAMINATHAN RAMESH
Director ceased
SATHISH KUMAR MOHAN RAO
13 May 2019
Director ceased
SHRIDHARA KELA
Director ceased
RAMAPRASAD JYOTHINAGARAVYASHA SRIRAMAN
13 May 2014
Charge satisfied
State Bank Of Hyderabad
15 Jul 2013
Securities allotted
3294941.00 Equity Shares - 16.47 cr raised
24 Dec 2012
Securities allotted
2056712.00 Equity Shares - 10.28 cr raised
30 Mar 2012
Securities allotted
3210000.00 Equity Shares - 16.05 cr raised
10
Key Observations
Auto-generated from the data aboveRevenue declined 1.42 over the last 4 financial year(s).
Debt-to-equity stands at 2.1x - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Lifesticks Pharmaceuticals Private Limited | U74999UR2020PTC011116 | Roorkee, Uttarakhand, India |
| Weinnovate Biosolutions | U74990PN2016PTC158762 | Pune, Maharashtra, India |
| Omicsgen Lifesciences | U74999KL2017PTC050248 | Kanayannur, Kerala, India |
| Tradeplus Ventures Private Limited | U24304OR2020PTC033456 | Bhubaneswar, Orissa, India |
| Rit Qik Homoeo Pharmaceuticals Private Limited | U74999TG2018PTC126291 | Yadadri Bhongir, Telangana, India |
| Aurobindo Hospitals Private Limited | U85100BR1996PTC007587 | Patna, Bihar, India |
| Oncostar Pharma Private Limited | U24100MH2014PTC254996 | Mumbai, Maharashtra, India |
| Sukhaya Pharmaceutical Private Limited | U74999MH2018PTC309990 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Sequent before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Sequent: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Enhanced diligence advised. Credit risk score 20/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Limited indicators at present. Growth score 40/100, margin trends, ownership structure and peer set for Sequent - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 72/100, distress signals and MSME payment-delay disclosures - know whether Sequent pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Sequent - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Sequent an active company?
Sequent has MCA status “Active” with a compliance score of 100/100 (Low Risk).
Is Sequent financially healthy?
Sequent has a Financial Health Score of 20/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Sequent?
Its overall Trust Score is 72/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Sequent?
The ultimate holding entity is Solara Active Pharma Sciences Limited. 2 active director(s) are on record.
Does Sequent have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.
Is Sequent up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).
Is it risky to lend to Sequent?
Its Credit Risk Score is 20/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
